Takeda licenses ovarian cancer drug Niraparib from US TESARO

The poly ADP-ribose polymerase (PARP) inhibitor (MK – 4827) is marketed in the US by TESARO Inc. as an oral drug for ovarian cancer maintenance therapy which can be administered independent of BRCA status of the patient. The agreement includes the development of...

NEDO starts program to reduce cost of wind power by 40 % in 2020

Members of the consortium are Yoshidado Co., Japan Ocean Drilling Co., Japan Marine United Co., Hitachi Zosen Corp., Kyoto University, Toyo Construction Co., TEPCO Holdings Co., Oobayashi Corp., TEPCO Design Co., Hitachi, Ltd., University of Tokyo, Kyushu University,...